IMR Press / FBS / Volume 14 / Issue 2 / DOI: 10.31083/j.fbs1402015
Open Access Original Research
Dynamic Profiling of Exosomal microRNAs in Blood Plasma of Patients with Castration-Resistant Prostate Cancer
Show Less
1 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
2 National Medical Research Radiological Center, Ministry of Health of the Russian Federation, 125284 Moscow, Russia
*Correspondence: (Elena A. Pudova)
Academic Editors: Poggi Alessandro and Neven Zarkovic
Front. Biosci. (Schol Ed) 2022, 14(2), 15;
Submitted: 28 February 2022 | Revised: 1 April 2022 | Accepted: 8 April 2022 | Published: 23 May 2022
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Prostate cancer is one of the most common and socially significant cancers among men. The aim of this study was to identify significant changes in the expression of exosomal miRNAs associated with an increase in the level of prostate specific antigen in castration-resistant prostate cancer during therapy and to evaluate them as potential prognostic markers for this category of disease. High-throughput miRNA sequencing was performed on 49 blood plasma samples taken from 11 Russian patients with castration-resistant cancer during therapy. Bioinformatic analysis of the obtained miRNA-seq data was carried out. Additionally, miRNA-seq data from the PRJNA562276 project were analyzed to identify exosomal miRNAs associated with castration-resistant prostate cancer. We found 34 differentially expressed miRNAs associated with the progression of castration-resistant prostate cancer during therapy in Russian patients. It was also shown that hsa-miRNA-148a-3p expression can serve as a potential prognostic marker. We found the exosomal miRNA expression signature associated with castration-resistant prostate cancer progression, in particular on the Russian patient cohort. Many of these miRNAs are well-known players in either oncogenic transformation or tumor suppression. Further experimental studies with extended sampling are required to validate these results.

castration-resistant prostate cancer
liquid biopsy
Fig. 1.
Back to top